Stryker (HAM:SYK) Cyclically Adjusted Revenue per Share: €50.61 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:SYK Stryker Corp HAM:SYK
92 GF Score
Price €282.60
GF Value €341.49
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Stryker Cyclically Adjusted Revenue per Share?

Stryker HAM:SYK +0.43% 92 Cyclically Adjusted Revenue per Share is €50.61 as of Jun. 2026. GuruFocus rates HAM:SYK with a GF Score™ of 92/100 and a GF Value™ of €341.49 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Stryker's adjusted revenue per share for the three months ended in Jun. 2026 was €14.817. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €50.61 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Stryker's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Stryker was 23.30% per year. The lowest was 7.90% per year. And the median was 11.50% per year.

As of today (2026-08-04), Stryker's current stock price is €282.60. Stryker's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €50.61. Stryker's Cyclically Adjusted PS Ratio of today is 5.58.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Stryker was 8.44. The lowest was 4.72. And the median was 6.89.


Stryker  (HAM:SYK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Stryker's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=282.60/50.61
=5.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Stryker was 8.44. The lowest was 4.72. And the median was 6.89.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Stryker Cyclically Adjusted Revenue per Share Related Terms


Stryker Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Stryker's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stryker Cyclically Adjusted Revenue per Share Chart

Stryker Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 43.86

Stryker Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 43.86 46.36 50.61

HAM:SYK vs MDT, ABT, BSX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Stryker's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stryker Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stryker's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Stryker's Cyclically Adjusted PS Ratio falls into.


HAM:SYK
92GF Score
Stryker Corp HAM:SYK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stryker Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Stryker's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.817/333.9520*333.9520
=14.817

Current CPI (Jun. 2026) = 333.9520.

Stryker Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.660 241.428 9.212
201612 7.895 241.432 10.920
201703 7.284 243.801 9.977
201706 7.058 244.955 9.622
201709 6.633 246.819 8.975
201712 7.698 246.524 10.428
201803 6.904 249.554 9.239
201806 7.481 251.989 9.914
201809 7.308 252.439 9.668
201812 8.781 251.233 11.672
201903 8.204 254.202 10.778
201906 8.512 256.143 11.098
201909 8.564 256.759 11.139
201912 9.779 256.974 12.708
202003 8.552 258.115 11.065
202006 6.536 257.797 8.467
202009 8.345 260.280 10.707
202012 9.190 260.474 11.782
202103 8.699 264.877 10.968
202106 9.323 271.696 11.459
202109 9.240 274.310 11.249
202112 10.883 278.802 13.036
202203 10.143 287.504 11.782
202206 11.121 296.311 12.534
202209 11.849 296.808 13.332
202212 12.848 296.797 14.456
202303 11.646 301.836 12.885
202306 12.012 305.109 13.148
202309 11.978 307.789 12.996
202312 13.897 306.746 15.130
202403 12.525 312.332 13.392
202406 13.070 314.175 13.893
202409 12.837 315.301 13.596
202412 15.915 315.605 16.840
202503 14.043 319.799 14.664
202506 13.512 322.561 13.989
202509 13.345 324.800 13.721
202512 15.845 324.054 16.329
202603 13.473 330.213 13.626
202606 14.817 333.952 14.817

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €50.61 mean?
Stryker (HAM:SYK) has a Cyclically Adjusted Revenue per Share of €50.61 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Stryker and its competitors.
Is Stryker's Cyclically Adjusted Revenue per Share too high?
Stryker's current Cyclically Adjusted Revenue per Share is €50.61. Overall, Stryker has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stryker's Cyclically Adjusted Revenue per Share compare to MDT and ABT?
Stryker's Cyclically Adjusted Revenue per Share of €50.61 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Stryker and its competitors. Stryker's current Cyclically Adjusted Revenue per Share is €50.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stryker stock overvalued right now?
Based on GuruFocus' analysis, Stryker (HAM:SYK) is currently considered Modestly Undervalued. The stock's GF Value™ is €341.49, compared to a current price of €282.60 — trading 17.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €50.61. Stryker's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Stryker (HAM:SYK), the current Cyclically Adjusted Revenue per Share is €50.61 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stryker (HAM:SYK) Overvalued in 2026?

Based on GuruFocus' analysis, Stryker stock appears to be undervalued. The current stock price of €282.60 is trading 17.2% below its estimated GF Value™ of €341.49. GuruFocus considers Stryker to be Modestly Undervalued.

Key valuation signals for HAM:SYK:

  • Cyclically Adjusted Revenue per Share: €50.61
  • GF Value™: €341.49 vs. price of €282.60 (17.2% below fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the HAM:SYK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Stryker Business Description

Address 1941 Stryker Way, Portage, MI, USA, 49002
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
92GF Score

Get the complete analysis for HAM:SYK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€282.60
Price
€341.49
GF Value